Table 1.
Comparison of patients with oJIAwith those with oligoarticular psJIA.
| Characteristic | oJIA* | psJIA* | p |
|---|---|---|---|
| N | 303 | 87 | n/a |
| Duration of follow-up (yrs: median, IQR*) |
3.8, 1.7 – 6.9 | 3.4, 1.3 – 5.6 | 0.147 |
| Females (%) | 80.9 | 69.0 | 0.018 |
| Age of onset (yrs: median, IQR) |
3.0, 1.8 – 5.7 | 6.1, 2.2 – 10.8 | < 0.001 |
| Age under five (%) | 71.0 | 43.7 | < 0.001 |
| Extended course (%) | 7.6 | 29.9 | < 0.001 |
| Affected joints (%) | |||
| Any large joint | 97.0 | 81.6 | < 0.001 |
| Shoulder | 0 | 0 | N/A |
| Elbow | 8.9 | 13.8 | 0.181 |
| Wrist | 12.5 | 27.6 | 0.001 |
| Hip | 1.3 | 3.4 | 0.188 |
| Knee | 83.8 | 60.9 | < 0.001 |
| Ankle / subtalar | 38.3 | 49.4 | 0.062 |
| Any small joint | 19.1 | 52.9 | < 0.001 |
| MCP* | 6.6 | 17.2 | 0.002 |
| Hand PIP* | 14.9 | 42.5 | < 0.001 |
| Hand DIP* | 0.7 | 10.3 | < 0.001 |
| MTP* | 2.0 | 14.9 | < 0.001 |
| Foot IP* | 2.3 | 10.3 | 0.003 |
| Extra-articular features (%) |
|||
| Psoriasis | 0 | 60.9 | < 0.001 |
| Nail pits | 3.6 | 48.3 | < 0.001 |
| Dactylitis | 16.8 | 50.6 | < 0.001 |
| Enthesitis | 0 | 27.6 | < 0.001 |
| Uveitis | 29/298, 9.7% | 6/57, 10.5% | 0.854 |
| Laboratory values | |||
| Baseline WBC / μl: mean, SD |
8.9, 2.6 | 8.6, 3.1 | 0.392 |
| Baseline ESR, mm/hr: mean, SD |
26.3, 20.4 | 21.1, 14.6 | 0.013 |
| Baseline platelets x 103 / μl: mean, SD |
375, 110 | 350, 84 | 0.069 |
| ANA | 215/299, 71.9% | 36/73, 49.3% | < 0.001 |
| RF | 8/269, 3.0% | 0/41 | 0.603 |
| HLA-B27 | 17/178, 9.6% | 3/25, 12.0% | 0.719 |
| Treatments (%) | |||
| IAC* | 43.2 | 21.8 | < 0.001 |
| Any traditional | 35.6 | 74.7 | < 0.001 |
| DMARD* | |||
| Any TNF* inhibitor | 7.6 | 18.4 | 0.003 |
*
Abbreviations: oJIA = oligoarticular juvenile idiopathic arthritis, psJIA = psoriatic juvenile idiopathic arthritis, IQR = inter-quartile range, MCP = metacarptal phalyngeal joint, PIP = proximal intraphalyngeal joint, DIP = distal intraphalyngeal joint, MTP = metatarsal phalyngeal joint, IP = intraphalyngeal joints, IAC = intra-articular corticosteroids, DMARD = disease-modifying anti-rheumatic drug, TNF = tumor necrosis factor.